Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 

31 protocols found



Protocol No. Title Status
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Open
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Not Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
NCI9782 A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Open
NRGGU003 A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post Prostatectomy Radiation Therapy (COPORT) Open
RTOG0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial Open
UW14083 A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Urethral-Sparing IMRT Planning Open
UW15014 Pilot trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients with Castration-Resistant, Metastatic Prostate Cancer Open
UW15052 Validation of Imaging-Based Biomarkers of Treatment Response in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide Open
UW15054 A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Open
UW15106 Genomic analysis of long-term survivors with metastatic cancer Open
UW16029 Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice Open (affiliates only)
UW16059 Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire Open
UW16062 PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Open
UW16107 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors Open
UW16116 A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers Open
UW16137 An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas Open
UW16140 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Open
UW17009 Pilot neoadjuvant trial of chemohormonal therapy followed by prostatectomy in patients with high risk and oligometastatic prostate cancer Open
UW17031 A Phase I Study of PCUR-101 in Combination with Androgen Suppression Therapy in the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer Open
UW17038 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial:(CANVAS Trial) Open
UW17055 A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW18001 A Multicenter, Open Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated with Cancer Open